• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Moderna Set to Join S&P 500

    7/15/21 7:01:00 PM ET
    $SPGI
    $ALXN
    $AZN
    $MRNA
    Finance: Consumer Services
    Finance
    Major Pharmaceuticals
    Health Care
    Get the next $SPGI alert in real time by email

    NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 21, 2021

    S&P 500

    Addition

    Moderna

    MRNA

    Health Care



    S&P 500

    Deletion

    Alexion Pharmaceuticals

    ALXN

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/moderna-set-to-join-sp-500-301335329.html

    SOURCE S&P Dow Jones Indices

    Get the next $SPGI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPGI
    $ALXN
    $AZN
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    More analyst ratings

    $SPGI
    $ALXN
    $AZN
    $MRNA
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    9/2/25 6:17:16 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/28/25 11:14:38 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/26/25 1:22:13 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TARIFF FEARS DRIVE U.S. STOCKPILING IN AUGUST, WHILE MANUFACTURING WEAKENS IN EUROPE AND ASIA: GEP SUPPLY CHAIN VOLATILITY INDEX

    North America's supply chains get busier, with sharp stockpiling of components to guard against tariff-driven shortages and price inflationAsia's manufacturers cut purchases, led by Japan and Taiwan, and to a lesser extent ChinaEurope weakens further, dragged down by Germany and a sharp downturn in the UKCLARK, N.J., Sept. 11, 2025 /PRNewswire/ -- GEP Global Supply Chain Volatility Index, a leading economic indicator based on a monthly survey of 27,000 businesses, slipped to -0.39 in August, from -0.35 in July, signaling rising spare capacity as global supply chain activity cooled. The global figure concealed stark regional contrasts. North America was the outlier, with supply chains running

    9/11/25 8:23:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global ushers new era of open data access: Introduces S&P Capital IQ Identifiers on DUNL.org

    Customers can reduce time to value by seamlessly accessing S&P Capital IQ Identifiers via DUNL.org New enhancement brings over 25 million company records in both human and machine-readable formatsNEW YORK, Sept. 11, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the availability of the S&P Capital IQ Identifiers on Data Unlocked (DUNL.org), a comprehensive open data portal that provides organizations worldwide with free access to essential reference and master data. The release further solidifies the S&P Capital IQ ID as the standard company identifier for all S&P Global data, with over 25 million companies now available in both human and machine-readable formats on DUNL.

    9/11/25 8:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer

    Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.EDINBURGH, Scotland and LONDON, Sept. 10, 2025 /PRNewswire/ -- Resolution Therapeutics ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces the appointment of Lucy Singah as Chief Financial Officer (CFO) and Daniel Kennedy as Chief Business Officer (CB

    9/10/25 3:30:00 AM ET
    $IMCR
    $ALXN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Pharmaceuticals

    Chief Legal Officer Klinger Shannon Thyme converted options into 232 shares and covered exercise/tax liability with 113 shares, increasing direct ownership by 0.42% to 28,170 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    9/2/25 5:26:23 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President Hoge Stephen converted options into 651 shares and covered exercise/tax liability with 315 shares, increasing direct ownership by 0.02% to 1,453,512 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    9/2/25 5:20:12 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 3% to 17,509 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    8/29/25 4:13:38 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

    Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

    4/15/25 12:40:56 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $600.00

    4/10/25 8:19:38 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Citigroup initiated coverage on Moderna with a new price target

    Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00

    3/13/25 8:15:14 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    AppLovin, Robinhood Markets and Emcor Group Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H

    9/5/25 6:34:00 PM ET
    $ACHC
    $APP
    $BGS
    Medical Specialities
    Health Care
    Computer Software: Programming Data Processing
    Technology

    Mirion Technologies Set to Join S&P SmallCap 600

    NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Mirion Technologies Inc. (NYSE:MIR) will replace GMS Inc. (NYSE:GMS) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 9. S&P 500 and 100 constituent Home Depot Inc. (NYSE:HD) acquired GMS in a deal that was completed today. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector September 9, 2025 S&P SmallCap 600 Addition Mirion Technologies MIR Information Technology September 9, 2025 S&P SmallCap 600 Deletion GMS GMS Industrials For more information about S&P Dow Jones Indices, please visit www

    9/4/25 5:28:00 PM ET
    $GMS
    $HD
    $MIR
    RETAIL: Building Materials
    Consumer Discretionary
    Industrial Machinery/Components
    Industrials

    S&P Global Announces Key Leadership Appointments for Mobility Business

    Scott Fredericks Named President of CARFAX Joe Lafeir to Serve as President of Mobility Business Solutions NEW YORK, Sept. 3, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of key leadership roles in the S&P Global Mobility ("Mobility") division, effective today. Scott Fredericks, current Chief Operating Officer of CARFAX, has been appointed President of CARFAX. He succeeds Bill Eager, who was recently appointed President of S&P Global Mobility and CEO designate upon completion of Mobility's planned separation from S&P Global into a standalone publ

    9/3/25 4:10:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Financials

    Live finance-specific insights

    View All

    Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial

    Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine Positive full results from the ​BaxHTN Phase III trial showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top

    8/30/25 10:19:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bill Eager Appointed President of S&P Global Mobility and CEO Designate of Planned Standalone Public Company

    Edouard Tavernier to Transition to Strategic Advisor Role Through September 30, 2025Company Separately Reports Second Quarter 2025 Results; Conference Call Today at 8:30 a.m. EDTNEW YORK, July 31, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Bill Eager, Chief Executive Officer of CARFAX, as President of S&P Global Mobility ("Mobility"), effective August 15, 2025, and CEO designate upon completion of the previously announced planned separation of Mobility into a standalone public company. Mr. Eager succeeds Edouard Tavernier, who will remain with the Company as a strategic advisor through September 30, 2025, to support a smooth transition.

    7/31/25 7:17:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Reports Second Quarter Results

    NEW YORK, July 31, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today reported second quarter results. The Company's earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings. Supplemental Information/Conference Call/Webcast Details:  The Company's senior management will review the second quarter 2025 earnings results on a conference call scheduled for today, July 31, at 8:30 a.m. EDT. Additional information presented on the conference call, as well as the Company's Supplemental slide content may be found on the Company's Inves

    7/31/25 7:16:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    4/10/24 2:03:52 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by S&P Global Inc. (Amendment)

    SC 13G/A - S&P Global Inc. (0000064040) (Subject)

    2/13/24 5:13:53 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    2/7/24 8:42:56 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care